
|Articles|September 1, 2006
Changing landscape of psoriasis therapy
Since the mid-1980s, mounting evidence has shown that psoriasis is an immune disorder - specifically, that abnormal T-cell activity is a critical component of the disease.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
2
Beyond the Plaques: How Psoriasis Shapes Work, Relationships, and Social Health
3
Sun Pharma’s Cosibelimab-ipdl (UNLOXCYT) Enters US Market for Advanced CSCC
4
Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types
5


















